EP2496256A2 - Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité - Google Patents

Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité

Info

Publication number
EP2496256A2
EP2496256A2 EP10828938A EP10828938A EP2496256A2 EP 2496256 A2 EP2496256 A2 EP 2496256A2 EP 10828938 A EP10828938 A EP 10828938A EP 10828938 A EP10828938 A EP 10828938A EP 2496256 A2 EP2496256 A2 EP 2496256A2
Authority
EP
European Patent Office
Prior art keywords
seq
antibody
immunoconjugate
poxvirus
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10828938A
Other languages
German (de)
English (en)
Other versions
EP2496256A4 (fr
Inventor
Alice P. Taylor
Boby Makabi-Panzu
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Molecular Medicine and Immunology
Original Assignee
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Center for Molecular Medicine and Immunology filed Critical Center for Molecular Medicine and Immunology
Publication of EP2496256A2 publication Critical patent/EP2496256A2/fr
Publication of EP2496256A4 publication Critical patent/EP2496256A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Definitions

  • the present invention relates to the design, generation and use of subunit-based vaccines for the treatment and/or prevention of poxvirus infections, including but not limited to smallpox.
  • the vaccines comprise an immunoconjugate of a subunit antigenic peptide derived from one or more viral proteins.
  • the viral proteins are immunomodulating factors, such as the viral IL-18 binding protein (vIL18BP), although alternative viral proteins may be used, such as viral envelope proteins.
  • subunit-based vaccines may comprise combinations of antigenic peptides from more than one viral protein, such as an
  • the viral antigenic peptide is attached to an antibody or antigen-binding fragment thereof that targets the subunit to antigen-producing cells (APCs).
  • the subunit-based vaccine incorporates an antibody or antibody fragment against the HLA-DR antigen, such as the L243 antibody; although the skilled artisan will realize that other APC targeting antibodies are known and may be used.
  • Use of the immunoconjugate provides substantially increased immunogenicity and improved immune system response against viral antigens, while avoiding the possibility of infection of immunocompromised individuals exposed to live virus-based vaccines.
  • the subunit-based vaccine is effective to induce immunity against and to prevent infection by smallpox and/or other poxviruses in vivo.
  • the Orthopoxviruses a group of complex viruses with cross-reacting antigens, includes vaccinia virus (VV), monkeypox virus, and the virus that causes smallpox (variola, VAR). Smallpox is no longer a naturally occurring infection, having been eradicated by a massive immunization program up to 1978, when routine vaccination of the world's population ceased (Minor, 2002, British Med J 62:213-224). At that time, the remaining stocks of virus were deposited in the U.S. and the former Soviet Union.
  • VV vaccinia virus
  • monkeypox virus monkeypox virus
  • VAR virus that causes smallpox
  • Smallpox is no longer a naturally occurring infection, having been eradicated by a massive immunization program up to 1978, when routine vaccination of the world's population ceased (Minor, 2002, British Med J 62:213-224). At that time, the remaining stocks of virus were deposited in the U.S. and the former Soviet Union.
  • Smallpox vaccine which employs active VV, currently represents the most effective means to immunize against smallpox (Rosenthal et al, 2001 , Emerg. Infect. Dis. 7: 920-926).
  • This vaccine produces a transient viremia which is resolved in most individuals, and which leaves long-lasting immunity.
  • this vaccine also raises safety issues because of serious adverse reactions, which include systemic viremia and death (He et al, 2007, JID 196: 1026-1032; Rosenthal et al, 2001). Therefore, development of alternative vaccination strategies is required if circumstances necessitate immunization of the population.
  • Attenuated forms of poxvirus such as the Akhara Modified Vaccinia (MVA), with deleted or mutated genes (Grandpre et al., Vaccine 27: 1549-56, 2009), may confer partial immunity to highly virulent strains of poxvirus. Immunization with inactivated virus has been
  • the present invention discloses improved compositions and methods of use of subunit vaccines against poxviruses, such as smallpox.
  • the vaccine comprises one or more subunit antigenic peptides conjugated to an antibody or antibody fragment that binds to antigen presenting cells (APCs), such as dendritic cells (DCs), to form an immunoconjugate.
  • APCs antigen presenting cells
  • DCs dendritic cells
  • Administration of the vaccine to subjects induces immunity against the poxvirus and is effective to treat or prevent poxvirus infection.
  • the vaccine may incorporate one or more adjuvants, such as aluminum hydroxide, CpG DNA, calcium phosphate or bacterial-based adjuvant (e.g., L. delbroeckii/bulgaricus) ..
  • vIL18BP viral interleukin-18 binding protein
  • IL-18BP viral interleukin-18 binding protein
  • IFN interferon-gamma
  • APCs antigen presenting cells
  • the subunit antigenic peptide is selected to mimic an epitope of vIL18BP.
  • Other exemplary host immune modulating factors and their locus_tag identifiers are provided in Table 1.
  • the subunit antigenic peptide is derived from a viral immunomodulating protein.
  • a viral immunomodulating protein The skilled artisan will realize that various viral
  • immunomodulating proteins are known and may be of use.
  • Non-limiting examples include the interferon-gamma (IFN-gamma) receptor homolog (B8R gene), complement control protein homolog (B5R gene) and serine protease inhibitors (B13R, B14R, B22R genes).
  • IFN-gamma interferon-gamma receptor homolog
  • B5R gene complement control protein homolog
  • serine protease inhibitors B13R, B14R, B22R genes.
  • poxvirus immunomodulatory proteins have been reported, although their effect on viral immunogenicity has not been well characterized. (See, e.g., Jackson et al.
  • B12R gene serotonin-1 and IL-6 receptor
  • B15R gene IL-1 and IL-6 receptor
  • B16R gene IL-1 receptor
  • B18R gene IFN-a receptor
  • B19R gene IL-1 and IL- 6 receptor, IFN inhibitor.
  • VACWROOl TNF-alpha receptor-like VACWR01 1 apoptosis
  • VACWR013 VAC WR C12L
  • VACWR025 blocks C3b/C4b complement activation
  • VACV A27L VACWR150 surface binding heparin sulfate
  • VACV D8L (VACWR1 13) surface binding chondroitin sulfate
  • VACV B5R (VACWR187) essential for membrane wrapping of IMV in trans-Golgi
  • the subunit antigenic peptide may be derived from a viral envelope protein or other viral proteins.
  • Non-limiting examples include the protein products of the D8L, A27L, L1R and A33R genes.
  • the skilled artisan will realize that the DNA and amino acid sequences of the various poxviral genes and proteins are well known in the art and are publicly available (see, e.g., GenBank Accession No. AY243312 for the complete genomic sequence of Vaccinia virus WR, along with the encoded protein sequences).
  • the antibody component of the immunoconjugate directs the complex to APCs, where the antigenic peptide component is processed to invoke an immune response against poxviruses and/or infected cells expressing the target antigen.
  • APC targeting antibodies are known in the art, such as antibodies that bind to an antigen selected from the group consisting of HLA-DR, CD74, CD209 (DC-SIGN), CD34, CD74, CD205, TLR 2 (tolllike receptor 2), TLR 4, TLR 7, TLR 9, BDCA-2, BDCA-3 and BDCA-4.
  • the antibody binds to an antigen selected from HLA-DR and CD74.
  • the antibody binds to HLA-DR.
  • the poxvirus vaccine comprises a humanized, human or chimeric anti-HLA-DR antibody, such as the L243 antibody.
  • the L243 antibody has been described (e.g., U.S. Patent No. 7,612,180, the Examples section of which is incorporated herein by reference) and is characterized by having heavy chain
  • CDR complementarity determining region
  • CDR1 NYGMN, SEQ ID NO: l
  • CDR2 WINTYTREPTYADDFKG, SEQ ID NO:2
  • CDR3 DITAVVPTGFDY, SEQ ID NO: 3
  • light chain CDR sequences CDR1 (RASENIYSNLA, SEQ ID NO:4)
  • CDR2 AASNLAD, SEQ ID NO:5
  • CDR3 OFWTTPWA, SEQ ID NO:6
  • anti-HLA-DR antibodies known in the art may be used (see, e.g., U.S. Patent Nos. 6,416,958, 6,894,149; 7,262,278, the Examples section of each of which is incorporated herein by reference).
  • the poxvirus vaccine comprises a humanized, human or chimeric anti-CD74 antibody, such as the LL1 antibody.
  • the LL1 antibody has been described (e.g., U.S. Patent No. 7,312,318, the Examples section of which is incorporated herein by reference) and is characterized by having light chain CDR sequences CDR1 (RSSQSLVHRNGNTYLH; SEQ ID NO:7), CDR2 (TVSNRFS; SEQ ID NO:8), and CDR3 (SQSSHVPPT; SEQ ID NO:9) and heavy chain CDR sequences CDR1 (NYGVN; SEQ ID NO: 10), CDR2 (WI PNTGEPTFDDDFKG; SEQ ID NO: l 1), and CDR3
  • the antibody or antigen-binding fragment thereof may be chimeric, humanized or human.
  • the use of chimeric antibodies is preferred to the parent murine antibodies because they possess human antibody constant region sequences and therefore do not elicit as strong a human anti-mouse antibody (HAMA) response as murine antibodies.
  • HAMA human anti-mouse antibody
  • the use of humanized antibodies is even more preferred, in order to further reduce the possibility of inducing a HAMA reaction.
  • techniques for humanization of murine antibodies by replacing murine framework and constant region sequences with corresponding human antibody framework and constant region sequences are well known in the art and have been applied to numerous murine anti-cancer antibodies.
  • Antibody humanization may also involve the substitution of one or more human framework amino acid residues with the corresponding residues from the parent murine framework region sequences. As also discussed below, techniques for production of human antibodies are also well known and such antibodies may be incorporated into the subject poxvirus vaccine constructs.
  • Still other embodiments relate to DNA sequences encoding fusion proteins, such as antibody-subunit antigenic peptide fusion proteins, vectors and host cells containing the DNA sequences, and methods of making fusion proteins for the production of poxvirus vaccines.
  • the fusion proteins may comprise DDD (dimerization and docking domain) moieties or AD (anchoring domain) moieties.
  • the immunoconjugate may be formed by chemical cross-linking of, for example, an antibody or antibody fragment and an antigenic peptide.
  • An antibody refers to a full-length (i.e., naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes) immunoglobulin molecule (e.g. , an IgG antibody) or an immunologically active, antigen-binding portion of an immunoglobulin molecule
  • immunoglobulin molecule like an antibody fragment.
  • an antibody fragment is a portion of an antibody such as F(ab') 2 , F(ab) 2 , Fab', Fab, Fv, scFv and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. Therefore the term is used synonymously with "antigen-binding antibody fragment.”
  • antibody fragment also includes isolated fragments consisting of the variable regions, such as the "Fv” fragments consisting of the variable regions of the heavy and light chains and recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker ("scFv proteins").
  • antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues.
  • Other antibody fragments for example single domain antibody fragments, are known in the art and may be used in the claimed constructs. (See, e.g., Muyldermans et al., TIBS 26:230-235, 2001 ; Yau et al., J Immunol Methods 281 : 161-75, 2003; Maass et al., J Immunol Methods 324: 13-25, 2007).
  • antibody fusion protein may refer to a recombinantly produced antigen- binding molecule in which one or more of the same or different single-chain antibody or antibody fragment segments with the same or different specificities are linked. Valency of the fusion protein indicates how many binding arms or sites the fusion protein has to a single antigen or epitope; i.e., monovalent, bivalent, trivalent or multivalent. The multivalency of the antibody fusion protein means that it can take advantage of multiple interactions in binding to an antigen, thus increasing the avidity of binding to the antigen. Specificity indicates how many antigens or epitopes an antibody fusion protein is able to bind; i.e., monospecific, bispecific, trispecific, multispecific.
  • a natural antibody e.g., an IgG
  • Monospecific, multivalent fusion proteins have more than one binding site for an epitope but only bind with one epitope.
  • the fusion protein may comprise a single antibody component, a multivalent or multispecific combination of different antibody components or multiple copies of the same antibody component.
  • the fusion protein may additionally comprise an antibody or an antibody fragment and a subunit peptide antigen.
  • the term is not limiting and a variety of protein or peptide effectors may be incorporated into a fusion protein.
  • a fusion protein may comprise an AD or DDD sequence for producing a DNL construct as discussed below.
  • a chimeric antibody is a recombinant protein that contains the variable domains including the complementarity determining regions (CDRs) of an antibody derived from one species, preferably a rodent antibody, while the constant domains of the antibody molecule are derived from those of a human antibody.
  • the constant domains of the chimeric antibody may be derived from that of other species, such as a cat or dog.
  • a humanized antibody is a recombinant protein in which the CDRs from an antibody from one species; e.g., a rodent antibody, are transferred from the heavy and light variable chains of the rodent antibody into human heavy and light variable domains (e.g., framework region sequences).
  • the constant domains of the antibody molecule are derived from those of a human antibody.
  • a limited number of framework region amino acid residues from the parent (rodent) antibody may be substituted into the human antibody framework region sequences.
  • a human antibody is, e.g., an antibody obtained from transgenic mice that have been "engineered” to produce specific human antibodies in response to antigenic challenge.
  • elements of the human heavy and light chain loci are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous murine heavy chain and light chain loci.
  • the transgenic mice can synthesize human antibodies specific for particular antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described by Green et al., Nature Genet. 7: 13 (1994), Lonberg et al., Nature 368:856 (1994), and Taylor et al., Int. Immun. 6:579 (1994).
  • a fully human antibody also can be constructed by genetic or chromosomal transfection methods, as well as phage display technology, all of which are known in the art.
  • antibody variable domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. In this way, the phage mimics some of the properties of the B cell.
  • Phage display can be performed in a variety of formats, for review, see e.g. Johnson and Chiswell, Current Opinion in Structural Biology 3 :5564-571 (1993). Human antibodies may also be generated by in vitro activated B cells. See U.S. Pat. Nos. 5,567,610 and 5,229,275, the Examples sections of which are incorporated herein by reference.
  • FIG. 1 Binding and uptake of peptides derived from vIL18BP sequence (SEQ ID NO:23).
  • Indicated peptides (TT830, SEQ ID NO: 19; vA4L229, SEQ ID NO: 18; vIL18BP008, SEQ ID NO: 13; vIL18BP105, SEQ ID NO: 15; vIL18BPl 10, SEQ ID NO: 16; vIL18BPl 17, SEQ ID NO: 17) were incubated with T2 cells for 24 h. Relative abundance of HLA-A02 on T2 cells is shown.
  • vIL18BP105 (SEQ ID NO: 15) demonstrated the highest uptake by donor PBMCs.
  • Duplicate samples were evaluated after incubation with the indicated biotinylated peptides for 24 h. NJ01 , NJ04, NJ07 and NJ08. Results were analyzed by flow cytometry after addition of an avidin-FITC conjugate. Fluorescence value for each peptide equals fluorescence value of peptide-treated cells minus the fluorescence value of untreated cells in the same experiment. Peptide concentration was 20 ⁇ .
  • FIG. 2 PBMCs from vaccinated donors proliferate when incubated with viral peptides.
  • CFSE-loaded PBMCs from vaccinated (A) and unvaccinated (B) human donors were incubated with 10 ⁇ g/mL of the designated peptide (vA27L003, SEQ ID NO:20;
  • vD8Ll 18, SEQ ID NO:22; vIL18BP105, SEQ ID NO: 15 or control for 5 days.
  • Cells were harvested and analyzed by flow cytometry (means + SD). Bars shown in order: open bars, medium control; solid black bars, 2.5 mg/niL peptide (or SEA); horizontal-hatch light-grey bars, 5.0 mg/mL peptide; vertical-hatch dark-grey bars, 10.0 mg/mL peptide.
  • C Results from separate experiments where cells from the designated samples were incubated with vD8Ll 18 (SEQ ID NO:22) to determine intracellular cytokine and activation marker expression. The results are shown in the embedded table (C) (D8L, vD8Ll 18 peptide, SEQ ID NO:22). * Group average P ⁇ 0.05 vs. medium controls (/-test).
  • FIG. 3 The responding CD8+ IFN-y+ cells have the phenotype of T EM or CD45RA- terminally differentiated cells.
  • CD8+ PBMCs from vaccinated donors were assessed for CD45RA and CCR7 expression.
  • the numbers represent percentage of total cells.
  • FIG. 4 CD 107a expression by CD8+ cells.
  • CD8+ cell population was assessed for IFN- ⁇ , IL-2 vs. degranulation potential marker CD 107a.
  • Numbers and bar values represent percentage of gated cells for (A) CD8+IFN-y+ cells, (B) CD8+IFN-y- cells, and (C) CD8+IL- 2+ cells. * group average P ⁇ 0.04 s. medium control (t-test).
  • FIG. 5 Antibody to peptides is present in serum from vaccinated donors. Serum from unvaccinated or vaccinated donors was diluted 1 :200 and incubated with peptide immobilized on 96-well plates in a modified ELISA for (A) peptide vA27L003 (SEQ ID NO:20), (B) peptide vD8Ll 10 (SEQ ID NO:21), and (C) peptide vIL18BP102 (SEQ ID NO: 14). Dots represent the A450 for each donor. * P ⁇ 0.03 vs. unvaccinated (ANOVA).
  • Unvaccinated donors 213, 704, 220; vaccinated donors: 05, 12A, 12B, 19, 26, 720, 308, 416, and 920.
  • Peptides vD8Ll 10 and vIL18BP105 were 25-mers which included the full sequences of vD8L 1 18 and vIL 18BP 105.
  • FIG. 6 HLA-DR04 tg splenocyte proliferation to vIL18BP 105.
  • FIG. 8 Binding of serum antibodies from immunized mice to intact vIL18BP protein. Serum from mice immunized with L243 antibody alone, vIL18BP105 peptide (SEQ ID NO: 15), the viral IL18BP105 peptide conjugated to L243 antibody (CIL18BP105), medium alone, or naive mice was tested for antibodies recognizing intact vIL18BP protein.
  • FIG. 9 Liposome based immunoconjugate for subunit vaccine.
  • A Liposome- displayed peptide-L243 antibody conjugate.
  • B Liposome-displayed bare peptide without antibody.
  • Poxviruses produce a spectrum of secreted host immune-response modifying factors which neutralize host cytokines and innate defense mechanisms. Weakening the host's first line of defense allows the virus to establish infection (e.g., in the mucosa) and then begin the first phase of infectious replication.
  • One factor produced by VV and other poxviruses is the viral interleukin-18 binding protein (vIL18BP, vaccinia virus C12L gene), expressed in the early phase of infection (Born et al. J Immunol 164:3246-54, 2000). It works by neutralizing a key pro-inflammatory cytokine, IL-18, which stimulates N , CD8, and Thl CD4 cells to produce interferon- ⁇ (IFN- ⁇ ), which directs acquired immunity toward the Thl type
  • PBMCs peripheral blood mononuclear cells
  • PBMCs peripheral blood mononuclear cells
  • peptides derived from other VV genes were also tested.
  • the D8L protein is important for viral attachment and entry into cells, and has been shown to elicit strong protective immunity in mouse models of poxvirus infection (Kan-Mitchell et al., J Immunol 172:5249-61, 2010; Berhanu et al, J Virol 82:3517-29, 2008).
  • the A27L protein is also important for viral attachment and assembly, and antibodies against it provide protective immunity (Berhanu et al., J Virol 82:3517-29, 2008; Chun g et al., J Virol 72: 1577-85, 1998; Scott, J Immunol 147:3149-55, 1991).
  • the overall goal of this invention was to select and develop T-cell (HLA-binding) and B- cell antigen peptides for inclusion in a multi-epitopic vaccine format.
  • Peptides have the advantages of being relatively easy to synthesize, modify, and combine into multi-antigen complexes.
  • the peptides were attached to antibodies targeting APCs, such as antibodies against the HLA-DR antigen.
  • DCs dendritic cells
  • APCs and DCs represent a promising approach for vaccination, as it can bypass the laborious and expensive ex vivo antigen loading and culturing, and facilitate large-scale application of immunotherapy (Tacken et al., Nat Rev Immunol. 2007, 7:790-802). More significantly, in vivo APC and/or DC targeting
  • B cells are another type of potent antigen-presenting cells capable of priming Thl/Th2 cells (Morris et al, J Immunol. 1994, 152:3777-3785; Constant, J Immunol. 1999, 162:5695-5703) and activating CD8 T cells via cross-presentation (Heit et al., J Immunol. 2004, 172:1501 -1507; Yan et al., Int Immunol. 2005, 17:869-773). It was recently reported that in vivo targeting of antigens to B cells breaks immune tolerance of MUC 1 (Ding et al., Blood 2008, 1 12:2817-25).
  • antibodies against antigens expressed by APCs in general and DCs in particular may be incorporated into
  • HLA-DR is a major histocompatibility complex class II cell surface receptor which functions in antigen presentation to elicit T-cell immune responses.
  • HLA-DR is found on a wide variety of antigen presenting cells, such as macrophages, B-cells and dendritic cells.
  • antigen presenting cells such as macrophages, B-cells and dendritic cells.
  • antibodies against HLA-DR including the L243 antibody, are known in the art. Such antibodies may be conjugated to subunit antigenic peptides for delivery to APCs.
  • CD74 is a type II integral membrane protein essential for proper MHC II folding and targeting of MHC II-CD74 complex to the endosomes (Stein et al., Clin Cancer Res. 2007, 13:5556s-5563s; Matza et al., Trends Immunol. 2003, 24(5):264-8). CD74 expression is not restricted to DCs, but is found in almost all antigen-presenting cells (Freudenthal et al., Proc Natl Acad Sci U S A. 1990, 87:7698-702; Clark et al., J Immunol. 1992, 148(1 1):3327-35).
  • CD74 in APCs may offer some advantages over sole expression in myeloid DCs, as targeting of antigens to other APCs like B cells has been reported to break immune tolerance (Ding et al., Blood 2008, 1 12:2817-25), and targeting to plasmacytoid DCs cross-presents antigens to naive CD8 T cells. More importantly, CD74 is also expressed in follicular DCs (Clark et al., J Immunol. 1992, 148(1 1):3327-35), a DC subset critical for antigen presentation to B cells (Tew et al., Immunol Rev. 1997, 156:39-52). This expression profile makes CD74 an excellent candidate for in vivo targeting vaccination.
  • anti-CD74 antibodies are known in the art, such as the LLl antibody (Leung et al., Mol Immunol. 1995, 32: 1416-1427; Losman et al., Cancer 1997, 80:2660-2666; Stein et al., Blood 2004, 104:3705-1 1).
  • antibodies or antigen-binding fragments of antibodies may be incorporated into the poxvirus vaccine.
  • Antigen-binding antibody fragments are well known in the art, such as F(ab') 2 , F(ab) 2 , Fab', Fab, Fv, scFv and the like, and any such known fragment may be used.
  • an antigen-binding antibody fragment refers to any fragment of an antibody that binds with the same antigen that is recognized by the intact or parent antibody. Techniques for preparing conjugates of virtually any antibody or fragment of interest are known (e.g., U.S. Patent No. 7,527,787).
  • monoclonal antibodies can be obtained by injecting mice with a composition comprising an antigen, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.
  • MAbs can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A SEPHAROSE®, size-exclusion chromatography, and ion-exchange
  • the antibodies can be sequenced and subsequently prepared by recombinant techniques. Humanization and chimerization of murine antibodies and antibody fragments are well known to those skilled in the art. The use of antibody components derived from humanized, chimeric or human antibodies obviates potential problems associated with the immunogenicity of murine constant regions.
  • a chimeric antibody is a recombinant protein in which the variable regions of a human antibody have been replaced by the variable regions of, for example, a mouse antibody, including the complementarity-determining regions (CDRs) of the mouse antibody.
  • Chimeric antibodies exhibit decreased immunogenicity and increased stability when administered to a subject.
  • CDRs complementarity-determining regions
  • a chimeric or murine monoclonal antibody may be humanized by transferring the mouse CDRs from the heavy and light variable chains of the mouse immunoglobulin into the corresponding variable domains of a human antibody.
  • the mouse framework regions (FR) in the chimeric monoclonal antibody are also replaced with human FR sequences.
  • additional modification might be required in order to restore the original affinity of the murine antibody. This can be accomplished by the replacement of one or more human residues in the FR regions with their murine counterparts to obtain an antibody that possesses good binding affinity to its epitope.
  • the claimed methods and procedures may utilize human antibodies produced by such techniques.
  • the phage display technique may be used to generate human antibodies (e.g., Dantas-Barbosa et al., 2005, Genet. Mol. Res. 4: 126-40).
  • Human antibodies may be generated from normal humans or from humans that exhibit a particular disease state, such as cancer (Dantas-Barbosa et al., 2005).
  • the advantage to constructing human antibodies from a diseased individual is that the circulating antibody repertoire may be biased towards antibodies against disease-associated antigens.
  • Fab fragment antigen binding protein
  • RNAs were converted to cDNAs and used to make Fab cDNA libraries using specific primers against the heavy and light chain immunoglobulin sequences (Marks et al., 1991 , J. Mol. Biol. 222:581-97).
  • Library construction was performed according to Andris-Widhopf et al. (2000, In: Phage Display Laboratory Manual, Barbas et al. (eds), 1 st edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY pp. 9.1 to 9.22).
  • Fab fragments were digested with restriction endonucleases and inserted into the bacteriophage genome to make the phage display library.
  • libraries may be screened by standard phage display methods, as known in the art (see, e.g., Pasqualini and Ruoslahti, 1996, Nature 380:364-366; Pasqualini, 1999, The Quart. J. Nucl. Med. 43: 159- 162).
  • Phage display can be performed in a variety of formats, for their review, see e.g. Johnson and Chiswell, Current Opinion in Structural Biology 3:5564-571 (1993). Human antibodies may also be generated by in vitro activated B-cells. See U.S. Patent Nos.
  • transgenic animals that have been genetically engineered to produce human antibodies may be used to generate antibodies against essentially any immunogenic target, using standard immunization protocols.
  • Methods for obtaining human antibodies from transgenic mice are disclosed by Green et al, Nature Genet. 7: 13 (1994), Lonberg et al, Nature 5(55:856 (1994), and Taylor et al, Int. Immun. 6:579 (1994).
  • a non- limiting example of such a system is the XenoMouse® (e.g. , Green et al., 1999, J. Immunol. Methods 231 : 1 1-23) from Abgenix (Fremont, CA).
  • the mouse antibody genes have been inactivated and replaced by functional human antibody genes, while the remainder of the mouse immune system remains intact.
  • the XenoMouse® was transformed with germline-configured YACs (yeast artificial chromosomes) that contained portions of the human IgH and Igkappa loci, including the majority of the variable region sequences, along accessory genes and regulatory sequences.
  • the human variable region repertoire may be used to generate antibody producing B-cells, which may be processed into hybridomas by known techniques.
  • a XenoMouse® immunized with a target antigen will produce human antibodies by the normal immune response, which may be harvested and/or produced by standard techniques discussed above.
  • a variety of strains of XenoMouse® are available, each of which is capable of producing a different class of antibody.
  • Transgenically produced human antibodies have been shown to have therapeutic potential, while retaining the pharmacokinetic properties of normal human antibodies (Green et al., 1999).
  • the skilled artisan will realize that the claimed compositions and methods are not limited to use of the XenoMouse® system but may utilize any transgenic animal that has been genetically engineered to produce human antibodies.
  • Antibody fragments which recognize specific epitopes can be generated by known techniques.
  • Antibody fragments are antigen binding portions of an antibody, such as F(ab') 2; Fab', F(ab) 2 , Fab, Fv, sFv and the like.
  • F(ab') 2 fragments can be produced by pepsin digestion of the antibody molecule and Fab ' fragments can be generated by reducing disulfide bridges of the F(ab') 2 fragments.
  • Fab ' expression libraries can be constructed (Huse et al. , 1989, Science, 246: 1274-1281) to allow rapid and easy identification of monoclonal Fab ' fragments with the desired specificity.
  • F(ab) 2 fragments may be generated by papain digestion of an antibody and Fab fragments obtained by disulfide reduction.
  • a single chain Fv molecule comprises a VL domain and a VH domain.
  • the VL and VH domains associate to form a target binding site. These two domains are further covalently linked by a peptide linker (L).
  • L peptide linker
  • Single domain antibodies may be obtained, for example, from camels, alpacas or llamas by standard immunization techniques. (See, e.g., Muyldermans et al., TIBS 26:230-235, 2001 ; Yau et al., J Immunol Methods 281 : 161-75, 2003; Maass et al., J Immunol Methods 324: 13-25, 2007).
  • the VHH may have potent antigen-binding capacity and can interact with novel epitopes that are inaccessible to conventional VH-VL pairs.
  • Alpaca serum IgG contains about 50% camelid heavy chain only IgG antibodies (HCAbs) (Maass et al., 2007).
  • Alpacas may be immunized with known antigens, such as TNF-a, and VHHs can be isolated that bind to and neutralize the target antigen (Maass et al., 2007).
  • PCR primers that amplify virtually all alpaca VHH coding sequences have been identified and may be used to construct alpaca VHH phage display libraries, which can be used for antibody fragment isolation by standard biopanning techniques well known in the art (Maass et al., 2007).
  • An antibody fragment can be prepared by proteolytic hydrolysis of the full length antibody or by expression in E. coli or another host of the DNA coding for the fragment.
  • An antibody fragment can be obtained by pepsin or papain digestion of full length antibodies by conventional methods. These methods are described, for example, by Goldenberg, U.S. Patent Nos. 4,036,945 and 4,331,647 and references contained therein. Also, see Nisonoff et al., Arch Biochem. Biophys. 59:230 (1960); Porter, Biochem. J. 75: 1 19 (1959), Edelman et al, in METHODS IN ENZYMOLOGY VOL. 1 , page 422 (Academic Press 1967), and Coligan at pages 2.8.1 -2.8.10 and 2.10.-2.10.4.
  • the poxvirus vaccine can alternatively be made by using an antibody that binds to or is reactive with another antigen on the surface of the target cell.
  • Preferred additional MAbs may comprise a humanized, chimeric or human MAb reactive with CD209 (DC-SIGN), CD34, CD205, TLR 2 (toll-like receptor 2), TLR 4, TLR 7, TLR 9, BDCA-2, BDCA-3 or BDCA-4.
  • Such antibodies may be obtained from public sources like the American Type Culture Collection or from commercial antibody vendors.
  • CD209(DC-SIGN), CD34, BDCA-2, TLR2, TLR 4, TLR 7 and TLR 9 may be purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
  • Antibodies against CD205 and BDCA-3 may be purchased from Miltenyi Biotec Inc. (Auburn, CA). Numerous other commercial sources of antibodies are known to the skilled artisan.
  • antibody sequences or antibody- secreting hybridomas against almost any APC-associated antigen may be obtained by a simple search of the ATCC, NCBI and/or USPTO databases for antibodies against a selected target antigen of interest.
  • the antigen binding domains of the cloned antibodies may be amplified, excised, ligated into an expression vector, transfected into an adapted host cell and used for protein production, using standard techniques well known in the art.
  • the poxvirus vaccine may be administered as an
  • immunoconjugate Many methods for making covalent or non-covalent conjugates with antibodies or fusion proteins are known in the art and any such known method may be utilized.
  • an antigenic peptide can be attached at the hinge region of a reduced antibody component via disulfide bond formation.
  • such agents can be attached using a heterobifunctional cross-linker, such as N-succinyl 3-(2-pyridyldithio)propionate (SPDP). Yu et al, Int. J. Cancer 56:244 (1994). General techniques for such conjugation are well-known in the art. See, for example, Wong, CHEMISTRY OF PROTEIN
  • subunit-based vaccines comprising immunoconjugates may be made by other techniques.
  • One technique for conjugating virtually any protein or peptide to any other protein or peptide is known as the dock-and-lock (DNL) technique.
  • DNL dock-and-lock
  • the DNL method exploits specific protein/protein interactions that occur between the regulatory (R) subunits of cAMP-dependent protein kinase (PKA) and the anchoring domain (AD) of A- kinase anchoring proteins (AKAPs) (Baillie et ah, FEBS Letters. 2005; 579:3264. Wong and Scott, Nat. Rev. Mol. Cell Biol. 2004; 5:959).
  • R regulatory
  • AD anchoring domain
  • AKAPs A- kinase anchoring proteins
  • PKA which plays a central role in one of the best studied signal transduction pathways triggered by the binding of the second messenger cAMP to the R subunits, was first isolated from rabbit skeletal muscle in 1968 (Walsh et al, J. Biol. Chem. 1968;243:3763).
  • the structure of the holoenzyme consists of two catalytic subunits held in an inactive form by the R subunits (Taylor, J. Biol. Chem. 1989;264:8443).
  • Isozymes of PKA are found with two types of R subunits (RI and RII), and each type has a and ⁇ isoforms (Scott, Pharmacol. Ther. 1991 ;50: 123).
  • the R subunits have been isolated only as stable dimers and the dimerization domain has been shown to consist of the first 44 amino-terminal residues (Newlon et al, Nat. Struct. Biol. 1999;6:222). Binding of cAMP to the R subunits leads to the release of active catalytic subunits for a broad spectrum of serine/threonine kinase activities, which are oriented toward selected substrates through the compartmentalization of PKA via its docking with AKAPs (Scott et al, J. Biol. Chem. 1990;265;21561).
  • AKAP microtubule-associated protein-2
  • the amino acid sequences of the AD are quite varied among individual AKAPs, with the binding affinities reported for RII dimers ranging from 2 to 90 nM (Alto et al, Proc. Natl. Acad. Sci. USA. 2003;100:4445). Interestingly, AKAPs will only bind to dimeric R subunits. For human Rlla, the AD binds to a hydrophobic surface formed by the 23 amino-terminal residues (Colledge and Scott, Trends Cell Biol. 1999; 6:216). Thus, the dimerization domain and AKAP binding domain of human Rlla are both located within the same N-terminal 44 amino acid sequence (Newlon et al., Nat. Struct. Biol. 1999;6:222; Newlon et al, EMBO J. 2001 ;20: 1651), which is termed the DDD herein.
  • Entity B is constructed by linking an AD sequence to a precursor of B, resulting in a second component hereafter referred to as b.
  • the dimeric motif of DDD contained in a 2 will create a docking site for binding to the AD sequence contained in b, thus facilitating a ready association of a 2 and b to form a binary, trimeric complex composed of a 2 b.
  • This binding event is made irreversible with a subsequent reaction to covalently secure the two entities via disulfide bridges, which occurs very efficiently based on the principle of effective local concentration because the initial binding interactions should bring the reactive thiol groups placed onto both the DDD and AD into proximity (Chmura et al, Proc. Natl. Acad. Sci. USA. 2001 ;98:8480) to ligate site-specifically.
  • the poxvirus vaccine immunoconjugates are based on a variation of the a 2 b structure, in which each heavy chain of an anti-HLA-DR or anti- CD74 antibody or F(ab')2 or F(ab) 2 antibody fragment is attached at its C-terminal end to one copy of an AD moiety. Since there are two heavy chains per antibody or fragment, there are two AD moieties per antibody or fragment. A subunit antigenic peptide is attached to a complementary DDD moiety.
  • each DDD dimer binds to one of the AD moieties attached to the IgG antibody or F(ab') 2 or F(ab) 2 fragment, resulting in a stoichiometry of four antigenic peptides per IgG or F(ab') 2 or F(ab) 2 unit.
  • alternative complexes may be utilized, such as attachment of the antigenic peptide to the AD sequence and attachment of the anti-HLA-DR or anti-CD74 MAb or fragment to the DDD moiety, resulting in a different stoichiometry of effector moieties.
  • a DNL complex may be constructed that comprises one antigenic peptide and one antibody or fragment.
  • site-specific ligations are expected to preserve the original activities of the two precursors.
  • This approach is modular in nature and potentially can be applied to link, site-specifically and covalently, a wide range of substances.
  • the DDD or AD moiety is covalently attached to an antibody or antigenic peptide to form a fusion protein or peptide.
  • a variety of methods are known for making fusion proteins, including nucleic acid synthesis, hybridization and/or amplification to produce a synthetic double-stranded nucleic acid encoding a fusion protein of interest. Such double-stranded nucleic acids may be inserted into expression vectors for fusion protein production by standard molecular biology techniques (see, e.g. Sambrook et al., Molecular Cloning, A laboratory manual 2 nd Ed, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989).
  • the AD and/or DDD moiety may be attached to either the N-terminal or C-terminal end of a protein or peptide.
  • site of attachment of an AD or DDD moiety may vary.
  • an AD or DDD moiety may be attached to either the N- or C-terminal end of an antibody or antibody fragment while retaining antigen-binding activity
  • attachment to the C- terminal end positions the AD or DDD moiety farther from the antigen-binding site and appears to result in a stronger binding interaction (e.g., Chang et al., Clin Cancer Res 2007, 13:5586s- 91s).
  • Site-specific attachment of a variety of effector moieties may be also performed using techniques known in the art, such as the use of bivalent cross-linking reagents and/or other chemical conjugation techniques.
  • the poxvirus vaccine can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the poxvirus vaccine is combined in a mixture with a pharmaceutically suitable excipient.
  • a pharmaceutically suitable excipient Sterile phosphate-buffered saline is one example of a pharmaceutically suitable excipient.
  • Other suitable excipients are well-known to those in the art. See, for example, Ansel et al, PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th Edition (Lea & Febiger 1990), and Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition (Mack Publishing Company 1990), and revised editions thereof.
  • the poxvirus vaccine is preferably administered either subcutaneously or nasally. More preferably, the poxvirus vaccine is administered as a single or multiple boluses via subcutaneous injection.
  • Formulations for administration can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • Control release preparations can be prepared through the use of polymers to complex or adsorb the poxvirus vaccine.
  • biocompatible polymers include matrices of poly(ethylene-co-vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid. Sherwood et al , Bio/Technology
  • the rate of release from such a matrix depends upon the molecular weight of the poxvirus vaccine, the amount of poxvirus vaccine within the matrix, and the size of dispersed particles. Saltzman et al , Biophys. J. 55: 163 (1989); Sherwood et al , supra.
  • solid dosage forms are described in Ansel et al , PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th Edition (Lea & Febiger 1990), and Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition (Mack Publishing Company 1990), and revised editions thereof.
  • the dosage of an administered poxvirus vaccine for humans will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history. It may be desirable to provide the recipient with a dosage of poxvirus vaccine that is in the range of from about 1 mg/kg to 25 mg/kg as a single administration, although a lower or higher dosage also may be administered as circumstances dictate.
  • therapeutic peptides may be administered by an inhalational route (e.g., Sievers et al., 2001 , Pure Appl. Chem. 73 : 1299-1303).
  • Supercritical carbon dioxide aerosolization has been used to generate nano or micro-scale particles out of a variety of pharmaceutical agents, including proteins and peptides (Id.)
  • Microbubbles formed by mixing supercritical carbon dioxide with aqueous protein or peptide solutions may be dried at lower temperatures (25 to 65°C.) than alternative methods of pharmaceutical powder formation, retaining the structure and activity of the therapeutic peptide (Id.)
  • stabilizing compounds such as trehalose, sucrose, other sugars, buffers or surfactants may be added to the solution to further preserve functional activity.
  • the particles generated are sufficiently small to be administered by inhalation.
  • nasal administration of an aqueous solution may be utilized.
  • kits containing components suitable for treating or diagnosing diseased tissue in a patient.
  • Exemplary kits may contain at least one or more poxvirus vaccine immunoconjugates as described herein.
  • a device capable of delivering the kit components through subcutaneous injection may be included.
  • One type of device is a syringe that is used to inject the composition into the body of a subject.
  • a therapeutic agent may be provided in the form of a prefilled syringe or autoinjection pen containing a sterile, liquid formulation or lyophilized preparation.
  • the kit components may be packaged together or separated into two or more containers.
  • the containers may be vials that contain sterile, lyophilized formulations of a composition that are suitable for reconstitution.
  • a kit may also contain one or more buffers suitable for reconstitution and/or dilution of other reagents.
  • Other containers that may be used include, but are not limited to, a pouch, tray, box, tube, or the like. Kit components may be packaged and maintained sterilely within the containers.
  • Another component that can be included is instructions to a person using a kit for its use.
  • Still other embodiments may concern DNA sequences comprising a nucleic acid encoding a poxvirus vaccine immunoconjugate, or its constituent proteins.
  • Fusion proteins may comprise an anti-HLA-DR antibody attached to a subunit antigenic peptide.
  • the encoded fusion proteins may comprise a DDD or AD moiety attached to an antibody or antigenic peptide.
  • Various embodiments relate to expression vectors comprising the coding DNA sequences.
  • the vectors may contain sequences encoding the light and heavy chain constant regions and the hinge region of a human immunoglobulin to which may be attached chimeric, humanized or human variable region sequences.
  • the vectors may additionally contain promoters that express the encoded protein(s) in a selected host cell, enhancers and signal or leader sequences. Vectors that are particularly useful are pdHL2 or GS.
  • the light and heavy chain constant regions and hinge region may be from a human EU myeloma immunoglobulin, where optionally at least one of the amino acid in the allotype positions is changed to that found in a different IgGl allotype, and wherein optionally amino acid 253 of the heavy chain of EU based on the EU number system may be replaced with alanine.
  • an IgGl sequence may be converted to an IgG4 sequence.
  • Peptide design 9-mer or 15-mers peptide sequences bearing multiple potential binding sites for both HLA class I and/or HLA class II molecules were derived from poxvirus open reading frames by visual screening for HLA anchor residues at the correct spacing, or by use of web-based methods (e.g., BIMAS or SYFPEITHI [Parker et al., J Immunol 152: 163-75, 1994; Rammensee et al., Immunogenetics 50:213-19, 1999]), with selection based on high potential for specific HLA-binding (Table 2).
  • web-based methods e.g., BIMAS or SYFPEITHI [Parker et al., J Immunol 152: 163-75, 1994; Rammensee et al., Immunogenetics 50:213-19, 1999]
  • VV antigens were retrieved from NIH GenBank, Accession number: AY243312. These peptides are designated by their gene source and a number (e.g., vIL18BP105 or vD8Ll 18).
  • Peptide amino acid sequences are shown below. Peptides were screened for similarities with the human genome, using the NIH Blast server
  • ALKDLMSSV (SEQ ID NO: 18)
  • Donor samples Buffy coats were obtained from the Blood Center of New Jersey (NJBB) (West Orange, NJ USA). Other PBMC samples were obtained from local donors after approval for use of human blood by the New England Institutional Review Board (Wellesley, MA USA), or from Cellular Technology Limited (CTL) (Shaker Hts, OH USA). Table 3 summarizes the donor HLA types, age, and vaccine status. Due to limited numbers of cells in each sample, not all samples were included in every assay.
  • Table 3 Summary of blood donor vaccine status, age, and HLA type.
  • DNA from donor PBMCs was amplified according to HLA-Typing kit (Biotest, Dreieich, Germany) specifications.
  • HLA type was provided for the CTL, Inc., samples.
  • Vaccinated donors were persons who either stated that they had previously received the live smallpox vaccine, or vaccination status was presumed based on age, while unvaccinated donors were persons who stated they had not received a smallpox vaccination or were born after vaccination ceased in the U.S. Due to limited numbers of cells in most samples, not all samples were tested in all assays.
  • PBMCs were typed for HLA by SSP-PCR using the Biotest kit (Biotest, Dreieich, Germany).
  • Peptide screening Transporter associated with antigen-processing protein- 1 and -2 (TAP1 and 2)-deficient human B/T hybridoma cell line, T2 cells (ATCC, Manassas, VA USA), which expresses surface HLA-A02 exclusively, and which increases its expression when stabilized by peptide in the antigen presentation groove (Nijman et al., Eur J Immunol 23 : 1215-19, 1993), was incubated with beta-2-microglobulin and peptides at the indicated concentrations. Due to TAP deficiency, peptides are not processed, and so must be of a length that allows binding to HLA-A02 (9-mer).
  • HLA HLA-binding protein
  • FITC-labed W6/32 BD Pharmingen, San Diego, CA USA
  • FACSCALIBURTM flow cytometer Becton Dickinson, San Jose, CA USA. Binding of the peptide epitopes to human PBMCs obtained from donors was detected by incubation of PBMCs at lxl0 6 /mL with biotinylated peptides, followed by addition of avidin-FITC conjugate to fixed cells, and flow cytometry.
  • peptides derived from the immunodominant poxvirus protein, A4L Bolanger et al., J Virol 72: 170-79, 1998), another from Tetanus Toxoid (TT830) (Demotz et al., J Immunol 142:394-402, 1989), or the HIV gag protein (HIVgag) (Kan-Mitchell et al., J Immunol 172:5249-61 , 2010), were included. Briefly, 10-50 x 10 6 PBMCs were labeled with CFSE (1.5 ⁇ ).
  • 2x10 5 cells (200 ⁇ ) were incubated with indicated concentrations of peptides, Staphylococcus aureus enterotoxin (SEA) (10 ng/mL), or phytohemagglutinin (2.5 ⁇ g/mL) (PHA, both from Sigma- Aldrich).
  • SEA Staphylococcus aureus enterotoxin
  • PHA phytohemagglutinin
  • 20,000 events, gated on live CD3+ lymphocytes were collected by flow cytometry, and analyzed using Flow- Jo software (Mountain View, CA USA). Proliferation was evaluated based on the reduction of CFSE fluorescence.
  • the fluorescence index (FI) of proliferating cells was calculated by dividing the number of cells losing CFSE dye in the presence of the stimulating peptide (test) by the number of cells proliferating in the absence of the peptide (control).
  • PBMCs in GOLGIPLUGTM (Brefeldin A, 1 ⁇ g/mL) were incubated with 10 ⁇ g/mL of the indicated peptides, medium control (with PBS added in same volume as peptide stock), or SEA or PHA, for 14 h. Cells were then surface- or
  • CD8-negative T cells were considered to contain the CD4+ population.
  • Antibody analysis A modified ELISA-based method (Makabi-Panzu et al., Vaccine 16: 1504-10, 1998) was used to assess serum antibody. Briefly, ELISA plate wells were coated with 10 ⁇ g/mL of target peptide. After blocking and washing, test sera were added in 2-fold serial dilutions in PBS. Binding of antibody was detected with peroxidase-conjugated anti-human antibody. Plates were developed with o-phenylenediamine dihydrochloride peroxidase substrate (Sigma- Aldrich, St. Louis, MO USA) and the optical density of wells was measured at 490 nm with an ELISA reader.
  • Poxyirus peptide design and screening Poxvirus vIL18BP (SEQ ID NO:23) was parsed into 9-, 15-, or 25-mer peptides based on a high score for HLA-binding potential according to the ranking system of SYFPEITHI or BIMAS, with emphasis on HLA-A02- and HLA-DR04-binding.
  • the vIL18BP-derived peptides were tested for binding to the TAP- deficient T2 hybridoma, which increases expression of HLA-A02 when stabilized by a peptide in the antigen-presenting groove.
  • vIL18BPl 10 (SEQ ID NO: 16), VIL18BP1 17(SEQ ID NO: 17), and A4L (SEQ ID NO: 18) all contain sequences with potential HLA-A0201 binding capability (without processing).
  • the vIL18BPl 17 (SEQ ID NO: 17) peptide despite moderate to high probability of binding HLA-A02, did not.
  • the 15-mer peptides incorporating the sequence of vIL18BPl 10 (SEQ ID NO: 16), which T2 cells cannot process (vIL18BP008, SEQ ID NO: 13 and 105, SEQ ID NO: 15).
  • vIL18BP peptides were also predicted to bind several other HLA haplotypes (Table 2), most of which were represented in the PBMC donor population, summarized in Table 3.
  • vIL18BP008 SEQ ID NO: 13, 15-mer
  • vIL18BPl 10 SEQ ID NO: 16, 9-mer
  • vIL18BPl 10 (SEQ ID NO: 16), a 9-mer, does not bind HLA- A01 , but binds HLA-A02, - A03, and -Al 1 , all of which were represented by T2 cells, or the donor panel.
  • vIL18BP105 SEQ ID NO: 15
  • HLA class II DR04 and DR15 NJ01 and NJ04
  • all of class I HLA types represented by the donors except HLA- A01.
  • donor NJ08 is HLA-A02-positive, thus HLA-A02 may account for the measured binding.
  • Evidence for binding of vILl 8BP105 (SEQ ID NO: 15) to HLA-DR16 is suggested by the strong signal from Donor NJ07, which expresses HLA-DR16 and non-binding HLA-A01.
  • FIG. 2A results for concurrent assays for vIL18BP105 (SEQ ID NO: 15), vD8Ll 18 (SEQ ID NO:22), and vA27L003 (SEQ ID NO:20) are shown in FIG. 2A (vaccinated donors) and FIG. 2B
  • vIL18BP105 (SEQ ID NO: 15), induced significant proliferation of PBMCs from vaccinated donors (Table 4) at a concentration of 10 ⁇ g/mL.
  • Vaccinated donor cells also proliferated when incubated with vD8Ll 18 (SEQ ID NO:22) (6 of 7) and vA27L003 (SEQ ID NO:20) (4 of 7, FIG. 2A).
  • vIL18BP105 SEQ ID NO: 15
  • vD8Ll 18 SEQ ID NO:22
  • vA27L003 SEQ ID NO:20
  • FI Fluorescence Index
  • Phenotype of proliferating cells To determine the CD4 or CD8 phenotype of the proliferating cells, CFSE-loaded PBMCs from vaccinated and unvaccinated controls incubated with either vA27L003 (SEQ ID NO:20) or vIL18BP105 (SEQ ID NO: 15), (5 days) were probed for CD4 or CD8 expression. Both CD4+ (4/5) and CD8+ (2/5) cells proliferated in samples from vaccinated donors, with little to no proliferation of either subset of cells in the unvaccinated donor samples (0 of 3, Table 5).
  • IL-2 production increased significantly in the CD4+ population (vD8Ll 18, SEQ ID NO:22) and in CD8+ cells (vIL18BP105, SEQ ID NO: 15) (Table 6; ⁇ 0.04).
  • Table 5 CD4+ or CD8+ phenotype of proliferating T cells incubated with vA27L003 or vIL18BP105 peptides (5-day assay).
  • CD8+/IFN-y-producing T cells from the same vaccinated donors were further analyzed for markers related to memory phenotype by staining for CD45RA, a marker of na ' ive and a subset of effector CD8 cells (TEMR A ), and CCR7, a lymph node homing marker.
  • This analysis differentiates between T CM (CCR7+CD45RA-), precursors (CCR7+CD45RA+), TEMRA (CCR7-CD45RA+), and T EM and terminally differentiated (CCR7-CD45RA-) cell populations.
  • the cell types that developed were CCR7-CD45RA- (TEM or terminally- differentiated effector) (FIG. 3).
  • vD8Ll 18 (SEQ ID NO:22) antigen peptide was most active in generating these cell types (P ⁇ 0.019 vs. medium controls).
  • 2 donors in each assay also responded similarly to vIL18BP105 (SEQ ID NO: 15), and vA27L003 (SEQ ID NO:20).
  • CD8+ effector cell population was assayed by determination of the expression of CD 107a (Berhanu et al., J Virol 82:3517-29, 2008) (FIG. 4).
  • CD 107a expression increased 2-7-fold in 3 of 5 PBMC samples incubated with vD8Ll 18 (SEQ ID NO:22) (P ⁇ 0.04).
  • CD8+IFN-y+ cells from unvaccinated donors were unresponsive to the peptides in similar 14-hour intracellular cytokine staining assays (not shown).
  • Serum antibody titers Antibody against poxvirus is required for protection upon secondary exposure, and the presence of anti-vaccinia antibody is maintained in 90% of vaccinees for decades after vaccination (Hammarlund et al, Nat Med 9: 1 131-37, 2003). Therefore, serum antibody from previously vaccinated patients would be directed toward immunologically relevant B-cell epitopes.
  • 1 :200 diluted sera from vaccinated and unvaccinated donors were tested with the peptides vA27L003 (SEQ ID NO:20) (15-mer), vIL18BP102, and vD8Ll 10 (25-mers). The results (FIG.
  • the epitopes were derived from three poxvirus antigens, including an antigen (vIL18BP) that is uncharacterized in host immunity, as well as the known poxviral envelope antigens, A27L and D8L, which are characterized for host protection, but for which specific epitopes are not characterized (Chung et al., J Virol 72: 1577-85, 1998; Hsaio et al., J Virol 73:8750-61, 1999). The types of responses elicited by each peptide varied.
  • Poxvirus IL18BP modulates host innate immunity by neutralizing N cell IL-18 which, in turn, prevents IFN- ⁇ production.
  • vIL18BP may aid in protection from initial infection, and therefore, establishment of infection, as was demonstrated recently for poxvirus type I IFN-binding protein (Xu et al., J Exp Med 205:981-92, 2008).
  • vIL18BP105 SEQ ID NO: 15
  • vD8Ll 18 SEQ ID NO:22
  • IFN- ⁇ production by peptide- stimulated CD8+ TEM cells has multiple effects, including induction of anti-viral effector function.
  • vD8Ll 18 (SEQ ID NO:22) stimulated CD8+ T cells with effector and proliferative potential
  • the results were similar to that reported for cells incubated with virus (Laouar et al, Plos One 3 :e4089, 2008).
  • IFN- ⁇ production also characterizes generation of a Thl response, which is necessary for development of cytotoxicity against vaccinia (Meseda et al., Clin Vaccine Immunol 16: 1261-71, 2009; Xu et al., J Immunol 172:6265-71, 2004).
  • production of IL-2 and IFN- ⁇ by CD4+ cells implicates helper Thl -oriented T- cell participation.
  • the A27L peptide did not stimulate increased IFN- ⁇ or IL-2 in CD8+ or CD4+ cells, even though T cells proliferated when incubated with this peptide.
  • the lack of activity in the A27L samples may be due to different kinetics of response, or stimulation of alternate populations of cells which produce different cytokines or interleukins, such as IL-4, for which we did not assay.
  • CD 107a a marker of cytolytic capacity
  • CD4+ cells from revaccinated donors expressed CD 107a upon stimulation by vaccinia virus
  • CD8+ cells from vaccinated donors demonstrated enhanced expression of this marker upon stimulation by the peptides.
  • subunit antigenic peptides from 3 poxvirus antigens are capable of stimulating recall responses from vaccinated donors, including T-cell proliferation, expression of cytokines, and serum antibody recognition of B- cell epitopes.
  • One antigenic epitope was from a heretofore uncharacterized host defense modulator produced by vaccinia, the IL18BP.
  • the results presented here show that development of an alternative vaccine against poxvirus using select peptide epitopes could produce immunity without the hazards of vaccination with active virus.
  • vIL18BP105 (SEQ ID NO: 15) was conjugated to the anti-HLA-DR antibody, L243, for better presentation to the immune system, and used to immunize HLA-DR04- expressing transgenic (tg) mice.
  • Conjugated vIL18BP105 (CIL18BP105) was more readily taken up by human and HLA-DR transgenic mouse cells than free vILl 8BP105 (SEQ ID NO: 15).
  • Splenocytes from HLA-DR04 transgenic mice immunized with CIL18BP105 proliferated in vitro when stimulated with vIL18BP105 (SEQ ID NO: 15). Proliferation of CIL18BP105-inoculated mouse splenocytes involved CD3+CD4+CD45RA- cells.
  • CIL18BP105-innoculated mice also showed early and rapidly rising titers of peptide-specific antibodies, 4 times that of vILl 8BP105-injected controls at day 7 after the first boost.
  • both CIL18BP105 and vIL18BP105 (SEQ ID NO: 15) induced IgG2a and IgGl, suggesting the initiation of both Thl and Th2 immunity.
  • Serum antibody from CIL18BP105- immunized mice recognized whole recombinant C12L protein.
  • HLA-DR antibody-conjugates Peptides that were found to stimulate proliferation of immune donor PBMCs were conjugated with L243 antibody using the heterobifunctional cross-linker, sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane- 1 -carboxylate (Sulfo- SMCC), "SMCC", containing H-hydroxysuccinimide (NHS) ester and maleimide groups, following the manufacturer's protocol (Pierce, Rockford, IL, USA).
  • SMCC interacts with primary amine of the antibody through its NHS ester groups to form amide bonds, and the maleimide groups form thioester bonds with the free sulfhydryl group of a C-terminal cysteine on the peptide.
  • 1 ml of a 1 mg/ml solution of antibody in PBS was reacted with 20 of a 1 mg/ml solution of freshly prepared SMCC in PBS for 2 hours at 4° C.
  • excess SMCC was removed through a PBS pre-equilibrated desalting column.
  • the activated antibody was collected and then incubated with the peptide (which bore a C-terminal cysteine) for another 2 hours (or overnight) at 4° C.
  • conjugate was purified by size exclusion using a P60 fine cross-linked bead column (BioRad, Hercules, CA, USA) to remove free peptide. Peptide conjugation efficiency was assessed by SDS-PAGE using a 5%-20% gradient gel. Before being injected into mice, conjugate preparations were filter-sterilized through a 0.22- ⁇ PVDF filter (Millipore, Bedford, MA), and emulsified in incomplete Freund's adjuvant (IF A).
  • P60 fine cross-linked bead column BioRad, Hercules, CA, USA
  • Peptide conjugation efficiency was assessed by SDS-PAGE using a 5%-20% gradient gel.
  • conjugate preparations were filter-sterilized through a 0.22- ⁇ PVDF filter (Millipore, Bedford, MA), and emulsified in incomplete Freund's adjuvant (IF A).
  • mice Six-to-eight week old female C57BL/6J (B6) transgenic (tg) mice expressing HLA-DR04 (HLA-DR tg) were obtained from Taconic (Germantown, NY, USA). Mice were maintained in a pathogen-free area of our facility. For immunizations, groups of 3 mice were primed, and then boosted twice at two-week intervals by the subcutaneous route, with 25 ⁇ g of vIL18BP105 (SEQ ID NO: 15) peptide emulsified in IFA in either free, or antibody-conjugated, form. Mice injected with IFA-emulsified PBS served as naive controls.
  • Spleen samples were collected at sacrifice. Serum for antibody detection and isotyping by ELISA was prepared from blood after overnight coagulation at 4° C. Splenocytes used in CFSE-based T-cell proliferation assays and TCR repertoire analysis, were isolated by mechanical disruption of spleens through stainless steel mesh.
  • Antibody production analysis and isotyping determination A modified ELISA- based method from a previous report was used (Makabi-Panzu et al, 1998) to assess antibody production and isotype. Briefly, ELISA plate wells were coated with 10 ⁇ of peptide in PBS and incubated overnight at 4°C. They were then blocked with skim milk/PBS for 30 minutes at 37°C and washed with PBS containing 0.05% Tween 20 (PBST). Test sera were either added in 2-fold serial dilution for antibody titer, or as a 1 :200 dilution for isotype determination. Plates were incubated with sera for 2 h at room temperature.
  • T-cell proliferation assay and TCRV ⁇ repertoire analysis T-cell proliferation for either donor PBMCs or murine splenocytes was assessed using a 5-day CFSE-based cell proliferation assay as reported previously (Younes et al, 2003). Briefly, 10-50 x 10 6 PBMC or splenocytes were labeled with CFSE at a final concentration of 1.5 ⁇ . Cells were washed twice in PBS and re-suspended in complete RPMI medium at 10 6 cells/ml. 2X10 5 cells were incubated with indicated concentrations of peptides or PHA (2.5 ⁇ g ml) for positive control wells.
  • washed splenocytes from immunized or naive mice were washed again with complete RPMI-1640 medium and with staining buffer, then pre-stained for T-cell surface markers as described above, for 20 min at 4° C, before being incubated again for 15 min at 4° C with the blocking 2.4G2 anti-FcRJII/I mAb.
  • the cells were then stained with an appropriate fluorescently labeled anti-TCRV ? antibody without removal of the FcR-blocking mAb. Following this last incubation, the cells were washed with stain buffer and analyzed by flow cytometry.
  • Humoral immunity to poxvirus is essential for protection against infection. Therefore, the antibody response against CIL18BP105 versus vIL18BP105 (SEQ ID NO: 15) was investigated in the immunized HLA-DR04 tg mice. The results are shown in FIG. 7. At day 7 after the first boost (day 21 after priming), CIL18BP105-injected mice displayed higher peptide-specific antibody production than mice injected with vIL18BP105 (SEQ ID NO: 15). But, at 14 days after the first boost, the amounts of antibody were similar.
  • IgGl and IgG2a isotypes were induced by CIL18BP105 and vIL18BP105 (SEQ ID NO: 15), but CIL18BP105 caused more production of IgGl antibodies than its free counterpart (not shown).
  • the production of IgGl and IgG2a suggests a mature antibody response with T-cell help.
  • Both Thl and Th2 helper cell participation is also suggested by this antibody response.
  • Serum antibody from CIL18BP105-immunized mice reacted strongly with whole vIL18BP protein (C12L) (FIG. 8), indicating that subunit antigenic peptide conjugated to anti-APC antibody is capable of inducing a systemic immune response against intact virions.
  • Immunization with CILl 8BP105 was more effective than immunization with vILl 8BP105 (SEQ ID NO: 15) at promoting interferon- ⁇ production from splenocytes stimulated in vitro with VIL18BP105 (SEQ ID NO: 15) peptide (Table 7).
  • a vaccine against poxvirus requires Thl and Th2 immune responses, cell-mediated and humoral immunity, and a suitable pool of memory CD4 T cells (Belyakoc et al, Proc. Natl. Acad. Sci. USA 100: 9458-9463, 2003).
  • the results presented show that sub-unit antigens conjugated to APC-targeting antibody can enhance and to induce Thl , Th2, and humoral immune responses.
  • mice (HLA-DR04 Tg) are anesthetized and vaccine is administered (15-25 ⁇ g peptide total) intranasally (i.n.) (10 ⁇ /nostril).
  • Vaccine is either free peptide, or peptide- L243 conjugate.
  • the adjuvant is the calcium phosphate adjuvant described by He et al. (Clin Diagnos Lab Immunol 9: 1021-1024, 2002) (10 ⁇ g/dose of antigen).
  • Controls consist of unimmunized (na ' ive) mice, mice immunized with the whole viral protein (i.n.), systemically immunized mice (peptide, sub-cutaneous (s.c.)), and mice immunized with carrier/adjuvant only (i.n.). Equal amounts of peptide are administered in each case. Mice are boosted twice using the same route as prime, at weeks 2 (dl4) and 4 (d28) after priming. Combinations of route of immunization may be employed (e.g., s.c. prime, followed by i.n. immunization on day 14).
  • mice from each treatment group are sacrificed at day 35 after prime immunization (25 of the 75 mice). Serum is harvested before priming immunization (dO), at day 7, 28, and 56. In addition nasal lavage (NL) fluids or bronchoalveolar lavage (BAL) and splenocytes are harvested at sacrifice.
  • dO priming immunization
  • NL nasal lavage
  • BAL bronchoalveolar lavage
  • Antigen-specific antibody in the respiratory tract fluids (gathered by NL or BAL upon sacrifice), and in the serum are titred by serial dilution and application to ELISA, with immobilized whole recombinant antigen (or vaccinia proteins), peptide, non-relevant peptide control and serially diluted serum from all treatment groups, including na ' ive mice. Isotype of specific antibodies is determined.
  • Neutralizing antibodies are present in mice immunized by either nasal or subcutaneous administration.
  • the antibodies react with both antigenic peptide and whole viral protein.
  • Nasal administration is more efficient to promote a mucosal immune response, while subcutaneous administration is more efficient to promote a systemic immune response against poxvirus.
  • the DNL technique can be used to make dimers, trimers, tetramers, hexamers, etc. comprising virtually any antibodies or fragments thereof or other protein or peptide moieties.
  • IgG antibodies, F(ab') 2 antibody fragments and subunit antigenic peptides may be produced as fusion proteins containing either a dimerization and docking domain (DDD) or anchoring domain (AD) sequence.
  • DDD and AD moieties are produced as fusion proteins, the skilled artisan will realize that other methods of conjugation, such as chemical cross-linking, may be utilized within the scope of the claimed methods and compositions.
  • DNL constructs may be formed by combining, for example, an Fab-DDD fusion protein of an anti-HLA-DR or anti-CD74 antibody with a vIL18BP105-AD fusion protein.
  • constructs may be made that combine IgG-AD fusion proteins with vIL18BP105-DDD fusion proteins.
  • the technique is not limiting and any protein or peptide of use may be produced as an AD or DDD fusion protein for incorporation into a DNL construct.
  • the AD and DDD conjugates are not limited to proteins or peptides and may comprise any molecule that may be cross-linked to an AD or DDD sequence using any cross-linking technique known in the art.
  • independent transgenic cell lines may be developed for each DDD or AD fusion protein. Once produced, the modules can be purified if desired or maintained in the cell culture supernatant fluid. Following production, any DDD-fusion protein module can be combined with any AD-fusion protein module to generate a DNL construct. For different types of constructs, different AD or DDD sequences may be utilized. Exemplary DDD and AD sequences are provided below.
  • DDD1 SHIQIPPGLTELLQGYTVEVLRQQPPDLVEFAVEYFTRLREARA (SEQ ID NO:24)
  • DDD2 CGHIQIPPGLTELLQGYTVEVLRQQPPDLVEFAVEYFTRLREARA (SEQ ID NO:25)
  • AD2 CGQIEYLAKQIVDNAIQQAGC (SEQ ID NO:27)
  • the plasmid vector pdHL2 has been used to produce a number of antibodies and antibody-based constructs. See Gillies et al., J Immunol Methods (1989), 125: 191-202; Losman et al, Cancer (Phila) (1997), 80:2660-6.
  • the di-cistronic mammalian expression vector directs the synthesis of the heavy and light chains of IgG.
  • the vector sequences are mostly identical for many different IgG-pdHL2 constructs, with the only differences existing in the variable domain (VH and VL) sequences. Using molecular biology tools known to those skilled in the art, these IgG expression vectors can be converted into Fab-DDD or Fab- AD expression vectors.
  • Fab-DDD expression vectors To generate Fab-DDD expression vectors, the coding sequences for the hinge, CH2 and CH3 domains of the heavy chain are replaced with a sequence encoding the first 4 residues of the hinge, a 14 residue Gly-Ser linker and the first 44 residues of human Rlla (referred to as DDD1).
  • DDD1 human Rlla
  • DDD1 human Rlla
  • AD1 AKAP-
  • Trimeric DNL construct are obtained by reacting a DDD fusion protein comprising, e.g., an IgG antibody or F(ab) antibody fragment with an AD fusion protein comprising, e.g., a subunit antigenic peptide, at a molar ratio of between 1.4: 1 and 2: 1.
  • the total protein concentration is 1.5 mg/ml in PBS containing 1 mM EDTA.
  • Subsequent steps may involve TCEP reduction, HIC chromatography, DMSO oxidation, and affinity chromatography to obtain the purified DNL construct. Addition of 5 mM TCEP rapidly results in the formation of a 2 b complex. Binding assays show that the antibody moiety and antigenic peptide moieties retain their functional properties of respectively antigen-binding and antigenicity.
  • any antibody or antibody fragment may be attached to any subunit antigenic peptide by preparing appropriate fusion proteins of each, comprising complementary DDD and AD moieties.
  • AD2 modules incorporating a linking sequence attaching a subunit vaccine peptide.
  • the AD2-peptide fusion is combined with DDD2-linked IgG or Fab moieties to provide a subunit based vaccine incorporating an APC-targeting antibody or antibody fragment.
  • a liposome formulation of antigenic peptide conjugated to L243 antibody was prepared by standard techniques.
  • the intranasal peptides were designed with linkers at both the C-terminal and N-terminal ends.
  • the C-terminal linker was used for conjugation of the L243 antibody.
  • the N-terminal linker was used to facilitate attachment to the liposome, via palmitoylation.
  • the peptide conjugates were as indicated below.
  • the CD8L1 18 peptide was not a lipoprotein and was encapsulated into liposomes.
  • FIG. 9(A) shows the results of nasal administration of a liposome formulated subunit vaccine. Peptides were prepared and conjugated to antibody as described in
  • FIG. 9 show T cell proliferation in response to incubation with the designated peptide in vitro after nasal immunization of mice.
  • the strongest effect on T cell proliferation was observed with the L1R183 antigenic peptide (SEQ ID NO:39) derived from the L1R antigen, an immunodominant intracellular mature virion (IMV) protein that offers post-exposure prophylaxis.
  • L1R183 antigenic peptide SEQ ID NO:39
  • IMV intracellular mature virion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des procédés et des compositions pour des vaccins à base de sous unité pour induire une immunité contre des infections par un poxvirus, telles que la variole. Des modes de réalisation préférés concernent des immunoconjugués comprenant un ou plusieurs peptides antigéniques de sous-unité attachés à un anticorps ou à un fragment de celui-ci qui cible des cellules de production d'antigènes (APC). Plus préférentiellement, l'anticorps se lie à HLA-DR et le peptide antigénique provient d'un facteur immunomodulateur, tel que la protéine virale de liaison à IL-18 (vIL18BP). Cependant, des mélanges de peptides antigéniques provenant de différentes protéines virales peuvent également être utilisés. Le vaccin est capable d'induire une immunité à l'encontre d'un poxvirus sans risque d'infection disséminée dans des hôtes immunocompromis ou de transmission à des contacts sensibles.
EP10828938.0A 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité Withdrawn EP2496256A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US25872909P 2009-11-06 2009-11-06
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US37805910P 2010-08-30 2010-08-30
PCT/US2010/054668 WO2011056721A2 (fr) 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité

Publications (2)

Publication Number Publication Date
EP2496256A2 true EP2496256A2 (fr) 2012-09-12
EP2496256A4 EP2496256A4 (fr) 2013-07-17

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10828938.0A Withdrawn EP2496256A4 (fr) 2009-11-05 2010-10-29 Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité

Country Status (6)

Country Link
EP (1) EP2496256A4 (fr)
CN (1) CN102573902A (fr)
AU (1) AU2010315432A1 (fr)
CA (1) CA2776563A1 (fr)
IN (1) IN2012DN02692A (fr)
WO (1) WO2011056721A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150238632A1 (en) * 2012-09-18 2015-08-27 University Of Washington Through Its Center For Commercialization Compositions and Methods for Delivery of Antigens to Plasmacytoid Dendritic Cells
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
CN108289952B (zh) 2015-11-19 2021-02-05 雷维托普有限公司 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
CN109187982B (zh) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 一种tlr类疫苗佐剂的筛选和鉴定方法
CA3117378A1 (fr) * 2018-10-22 2020-04-30 Icellkealex Therapeutics Llc Virus de la vaccine mutants et leur utilisation
CN111474339A (zh) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 一种利用荧光标记痘病毒颗粒的方法及其应用
CN115867312A (zh) * 2020-04-27 2023-03-28 杰诺维有限公司 产生引发针对病毒的非病毒粒子组成衍生表位的人白细胞抗原i类限制性cd8 t细胞应答的疫苗组合物的方法

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (fr) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Polypeptide de fusion au vih
WO1999036507A1 (fr) * 1998-01-15 1999-07-22 Genitrix, Llc Compositions de vaccin et procedes de modulation des reponses immunitaires
US20010014327A1 (en) * 1995-06-07 2001-08-16 Naveen N Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
US20020040130A1 (en) * 2000-07-10 2002-04-04 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030198595A1 (en) * 1998-06-22 2003-10-23 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2004094613A2 (fr) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Complexe proteinique polyvalent
WO2006107786A2 (fr) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Structures ameliorees, attachees de façon stable, de compositions definies presentant diverses fonctions ou specificites de liaison
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007046893A2 (fr) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Procedes et compositions permettant de produire des ensembles bioactifs de complexite augmentee et utilisations
US20070140966A1 (en) * 2005-10-19 2007-06-21 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007075270A2 (fr) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Ensembles bio-actifs polyvalents a base d'immunoglobuline
WO2007134037A2 (fr) * 2006-05-15 2007-11-22 Immunomedics, Inc. Procédés et compositions de traitement d'infections par le virus de l'immunodéficience humaine avec des anticorps ou des fragments d'anticorps conjugués
WO2009055653A1 (fr) * 2007-10-26 2009-04-30 Ibc Pharmaceuticals, Inc. Pegylation par la technique d'accostage et verrouillage (dnl)
US20090191225A1 (en) * 2005-04-06 2009-07-30 Ibc Pharmaceuticals, Inc. Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities
US20090202487A1 (en) * 2005-04-06 2009-08-13 Ibc Pharmaceuticals, Inc. Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
WO2009126558A1 (fr) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Procédé modulaire pour préparer des cytokines tétramères avec une pharmacocinétique améliorée par la technologie « dock-and-lock » (dnl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395422T1 (de) * 1995-06-07 2008-05-15 Sanofi Pasteur Ltd Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
EP2308898B1 (fr) * 2002-03-01 2016-06-08 Immunomedics, Inc. Internalisation d'anticorps anti-CD74 et procédés d'utilisation
CA2599734C (fr) * 2005-03-03 2014-01-28 Immunomedics, Inc. Anticorps humanises l243
WO2006113927A2 (fr) * 2005-04-20 2006-10-26 University Of Washington Peptides de la vaccine immunogenes et procedes d'utilisation de ces peptides

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (fr) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Polypeptide de fusion au vih
US20010014327A1 (en) * 1995-06-07 2001-08-16 Naveen N Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
WO1999036507A1 (fr) * 1998-01-15 1999-07-22 Genitrix, Llc Compositions de vaccin et procedes de modulation des reponses immunitaires
US20030198595A1 (en) * 1998-06-22 2003-10-23 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20020040130A1 (en) * 2000-07-10 2002-04-04 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2004094613A2 (fr) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Complexe proteinique polyvalent
WO2006107786A2 (fr) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Structures ameliorees, attachees de façon stable, de compositions definies presentant diverses fonctions ou specificites de liaison
US20090191225A1 (en) * 2005-04-06 2009-07-30 Ibc Pharmaceuticals, Inc. Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities
US20090202487A1 (en) * 2005-04-06 2009-08-13 Ibc Pharmaceuticals, Inc. Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007046893A2 (fr) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Procedes et compositions permettant de produire des ensembles bioactifs de complexite augmentee et utilisations
US20070140966A1 (en) * 2005-10-19 2007-06-21 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007075270A2 (fr) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Ensembles bio-actifs polyvalents a base d'immunoglobuline
WO2007134037A2 (fr) * 2006-05-15 2007-11-22 Immunomedics, Inc. Procédés et compositions de traitement d'infections par le virus de l'immunodéficience humaine avec des anticorps ou des fragments d'anticorps conjugués
WO2009055653A1 (fr) * 2007-10-26 2009-04-30 Ibc Pharmaceuticals, Inc. Pegylation par la technique d'accostage et verrouillage (dnl)
WO2009126558A1 (fr) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Procédé modulaire pour préparer des cytokines tétramères avec une pharmacocinétique améliorée par la technologie « dock-and-lock » (dnl)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. M. GOLDENBERG ET AL: "Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting", THE JOURNAL OF NUCLEAR MEDICINE, vol. 49, no. 1, 1 January 2008 (2008-01-01), pages 158-163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 *
See also references of WO2011056721A2 *

Also Published As

Publication number Publication date
CA2776563A1 (fr) 2011-05-12
CN102573902A (zh) 2012-07-11
WO2011056721A2 (fr) 2011-05-12
WO2011056721A3 (fr) 2011-10-13
EP2496256A4 (fr) 2013-07-17
IN2012DN02692A (fr) 2015-09-04
AU2010315432A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
US20110064754A1 (en) Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
EP2496256A2 (fr) Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité
US8883160B2 (en) Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CN106414500B (zh) 抗-wt1/hla双特异性抗体
US9623115B2 (en) Dock-and-Lock (DNL) Complexes for Disease Therapy
ES2330017T3 (es) Ligandos de cd40 y peptidos de ctl para tratar tumores.
CN118388656A (zh) 用于治疗表达密蛋白之癌症疾病的与密蛋白6或密蛋白18.2和cd3结合的双特异性三价抗体
JP7169298B2 (ja) ヒトアルファフェトタンパク質特異的ｔ細胞受容体およびその使用
CN109195994A (zh) 针对cd137的新型双特异性多肽
US20130164214A1 (en) Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
BR112020021111A2 (pt) anticorpo multiespecífico, ácido nucleico e formulação farmacêutica
AU2017250191A1 (en) Anti-PSMA antibodies and use thereof
KR20220093103A (ko) 항종양용해 바이러스 항원 항체 및 이의 사용 방법
TW202334405A (zh) 假型分型之病毒顆粒、包含其之組合物及其用途
JP2023528017A (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
WO2014043215A1 (fr) Dianticorps bispécifiques pour le masquage et le ciblage de vaccins
US9550838B2 (en) Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CN113412123A (zh) 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
WO2014039840A1 (fr) Compositions de vaccin contre le vih et procédés associés
KR20240137086A (ko) Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
KR20230008162A (ko) 암 및 감염성 질환에 대한 면역요법을 위한 융합 단백질
CA3177288A1 (fr) Polytherapie faisant intervenir des pbmc modifiees et un immunoconjugue
US20170088635A1 (en) Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
AU2008238215B2 (en) Ig-pConsensus gene vaccination protects from antibody-dependent immune pathology in autoimmune disease
CN112955175A (zh) 增强抗体依赖性细胞介导的细胞毒性（adcc）的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130619

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/56 20060101ALI20130613BHEP

Ipc: C07K 16/28 20060101ALI20130613BHEP

Ipc: A61K 47/48 20060101ALI20130613BHEP

Ipc: C07K 14/52 20060101ALI20130613BHEP

Ipc: A61P 35/00 20060101ALI20130613BHEP

Ipc: C07K 16/46 20060101AFI20130613BHEP

Ipc: C07K 16/24 20060101ALI20130613BHEP

Ipc: C07K 16/30 20060101ALI20130613BHEP

Ipc: C07K 16/44 20060101ALI20130613BHEP

Ipc: A61K 39/395 20060101ALI20130613BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150401